Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 443 • 2017 ACR/ARHP Annual Meeting
Methotrexate Treatment Strategies in an Early Rheumatoid Arthritis Cohort
Sasha Bernatsky¹, Orit Schieir², Cristiano S. Moura³, Marie-France Valois⁴, Susan J. Bartlett⁵, Carol A Hitchon⁶, Janet E. Pope⁷, Gilles Boire⁸, Boulos Haraoui⁹, Edward C. Keystone¹⁰, Diane Tin¹¹, Carter Thorne¹² and Vivian P. Bykerk¹³, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁹Institute de Rheumatologie, Montreal, QC, Canada, ¹⁰Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Newmarket, ON, Canada, ¹³2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is recommended as part of initial therapy in early RA, but practices range widely. The objective of this analysis was to describe…
Abstract Number: 1903 • 2017 ACR/ARHP Annual Meeting
Can Achieving Sustained DAS Remission Prevent Arterial Stiffness Progression in Early Rheumatoid Arthritis – a Post-Hoc Analysis of a Randomized Controlled Study
Lydia Ho Pui Tam¹, Qing SHANG², Edmund Li³, Priscilla WONG³, Kitty Y Kwok⁴, Emily W Kun⁵, Issac C Yim⁶, Violet KL Lee⁷, Ronald ML Yip⁸, Steve H Pang⁸, Virginia W Lao⁸, Queenie Mak¹, Tsz Ho CHENG¹, Xerox Lau¹, Tena K. Li⁹, Tracy Y. ZHU¹⁰, PW Alex LEE¹ and Lai-Shan Tam², ¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁵Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁶Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, ⁷Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong, ⁸Department of Medicine, Kwong Wah Hospital, Hong Kong, Hong Kong, ⁹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ¹⁰Bone Quality and Health Center of the Department of Orthopedics & Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher incidence of cardiovascular disease (CVD) and prevalence of arterial stiffness (AS) due to chronic inflammation. AS…
Abstract Number: 486 • 2017 ACR/ARHP Annual Meeting
Anti-Citrullinated Protein Antibody Reactivities in Treatment NaïVe Early Rheumatoid Arthritis
Maria K. Jonsson^1,2, Aase Hensvold³, Monika Hansson⁴, Linda Mathsson-Alm⁵, Anna-Birgitte Aga², Joseph Sexton², Bjørg-Tilde Fevang^1,6, Siri Lillegraven², Anca I. Catrina³ and Espen A. Haavardsholm^2,7, ¹Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Karolinska Institute, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁵Thermo Fisher Scientific, Uppsala, Sweden, ⁶Dept. of Clinical Science, University of Bergen, Bergen, Norway, ⁷University of Oslo, Oslo, Norway
Background/Purpose: Anti-citrullinated protein antibody (ACPA) reactivities can precede RA onset, and may be involved in the pathogenesis of the disease. We wanted to assess the…
Abstract Number: 1994 • 2017 ACR/ARHP Annual Meeting
Erosion Depth Predicts Erosion Progression in Patients with Early RA: A Longitudinal Analysis Using HR-pQCT
Jiang YUE¹, James F Griffith², Fan XIAO³, Jiankun XU⁴, Ling Qin⁵ and Lai-Shan Tam⁶, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, HONGKONG, Hong Kong, ³Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Orthopedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁵Bone Quality and Health Centre of the Department of Orthopaedics and Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, hongkong, Hong Kong, ⁶Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: To ascertain the predictors of erosion progression in patients with early RA using high-resolution peripheral quantitative computed tomography (HR-pQCT). Methods: In this prospective study,…
Abstract Number: 918 • 2017 ACR/ARHP Annual Meeting
Development and Validation of a Clinical Rule to Facilitate Recognition of Clinical Arthritis By General Practitioners
Robin M ten Brinck¹, Bastiaan T van Dijk², Hanna W van Steenbergen¹, Saskia le Cessie³, Mattijs E Numans⁴ and Annette H.M. van der Helm-van Mil¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medical statistics and Epidemiology, Department of Medical Statistics and Epidemiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Early treatment of rheumatoid arthritis requires the early detection of arthritis. This is generally done by joint examination and difficult for general practitioners (GPs).…
Abstract Number: 1997 • 2017 ACR/ARHP Annual Meeting
Detection of Progression of Radiographic Damage Despite Early and Targeted Therapy in Inflammatory Arthritis Using High-Resolution Peripheral Quantitative Computed Tomography
Sarah Manske^1,2, Stephanie Finzel³, Steven K. Boyd⁴ and Cheryl Barnabe⁵, ¹Department of Radiology, University of Calgary, Calgary, AB, Canada, ²McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, AB, Canada, ³Department of Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁴Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Early initiation of DMARDs and targeted therapy to achieve remission are said to offer the best opportunity to prevent radiographic damage in early inflammatory…
Abstract Number: 1095 • 2016 ACR/ARHP Annual Meeting
Periarticular Bone Loss in Arthritis Is Induced By Autoantibodies Against Citrullinated Vimentin
Cecilia Engdahl¹, Holger Bang², Katharina Dietel¹, Stefanie C Lang¹, Ulrike Harre¹ and Georg Schett³, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ²Orgentec Diagnostics, Mainz, Germany, ³Department of Internal Medicine III, Institute for Clinical Immunology,, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany
Background/Purpose: Periarticular bone loss is a long known and early but yet insufficiently understood phenomenon in patients with rheumatoid arthritis. This study investigated whether autoimmunity…
Abstract Number: 2545 • 2016 ACR/ARHP Annual Meeting
Physicians, but Not Patients, Agree That EULAR Good Response Indicates Remission after 12 Weeks Treatment of Early Rheumatoid Arthritis
Samina A. Turk¹, Dirkjan van Schaardenburg^1,2, Linda A. Rasch³, Véronique Lugt¹, Willem F. Lems^1,3, Mike T. Nurmohamed^1,4 and Lilian van Tuyl³, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: The Disease Activity Score (DAS) and the European League Against Rheumatism (EULAR) response criteria are commonly used to describe disease activity in Rheumatoid Arthritis…
Abstract Number: 12 • 2016 ACR/ARHP Annual Meeting
Benefit of Early Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid Arthritis and Undifferentiated Early Arthritis (CONAART)
Soledad Retamozo¹, Maria Jezabel Haye Salinas², Juan Pablo Pirola³, Diego Baenas², Ana C. Alvarez⁴, Veronica Saurit³, Alejandro Alvarellos⁵, Christian A. Waimann⁶, Gustavo Citera^7,8, Fernando Dal Pra⁹, Celeste Orozco⁹, Federico Ceccato¹⁰, Sergio Paira¹⁰, MV Martire¹¹, G Crespo Amaya¹¹, Anastasia Secco¹¹, M Mamani¹¹, Javier Rosa¹², Enrique Soriano¹², Josefina Marcos¹³, Mercedes Argentina García¹⁴, Carolina Costi¹⁵, María M Zalazar¹⁶, Alejandro Martinez Muñoz¹⁶, Oscar Luis Rillo¹⁷, Horacio Berman¹⁸, Alberto Berman¹⁸, Francisco Colombres¹⁸, Edson Javier Velozo¹⁹, Vicente Ricardo Juarez²⁰, M Crespo²⁰, A Quinteros²¹, M Leal²¹, G Salvatierra²², Monica Sacnún²³, R Quintana²³, M Abdala²⁴ and Francisco Caeiro²⁵, ¹Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ²Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ³Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ⁴Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina, ⁵Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ⁶Escuela Superior de Ciencias de la Salud, UNICEN., Olavarria,, Argentina, ⁷Rheumatology, Instituto de Rehabilitacion Psicofisica - Fundacion Reumatologica Argentina Dr. Osvaldo Garcia-Morteo, Buenos Aires, Argentina, ⁸Rheumatology, CONAART - IREP, Buenos Aires, Argentina, ⁹Instituto De Rehabilitación Psicofísica, Argentina, CABA, Argentina, ¹⁰Hospital Dr José María Cullen, Santa Fe, Argentina, ¹¹Hospital Bernardino Rivadavia, CABA, Argentina, ¹²Hospital Italiano De Buenos Aires, CABA, Argentina, ¹³Hospital San Martin, La Plata, Argentina, ¹⁴Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, ¹⁵Hospital San Martín, LaPlata, Argentina, ¹⁶Hospital Pirovano, CABA, Argentina, ¹⁷Rheumatology Department, Hospital General de Agudos “Dr. Ignacio Pirovano”, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁸Centro Médico Privado De Reumatología (Tucumán), Tucumán, Argentina, ¹⁹Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, ²⁰Hospital Señor Del Milagro, Salta, Argentina, ²¹Centro Integral De Reumatología, Tucumán, Argentina, ²²Instituto Provincial De Rehabilitación Integral, Santiago del Estero, Argentina, ²³Hospital Provincial De Rosario, Rosario, Argentina, ²⁴Hospital Provincial Del Centenario, Rosario, Argentina, ²⁵Rheumatology, Hospital Privado Centro Medico De Córdoba, Cordoba, Argentina
Background/Purpose: To analyze clinical remission in patients with early RA and undifferentiated arthritis (UA) during the first 2 years of treatment using methotrexate (MTX) and…
Abstract Number: 1198 • 2016 ACR/ARHP Annual Meeting
Gene Enrichment Analysis Identifies Active CD40-CD40L Signaling in Early and Established Rheumatoid Arthritis
Yanxia Guo¹, Alice Walsh¹, Ursula Fearon², Malcolm D. Smith³, Mihir D Wechalekar⁴, Xuefeng Yin¹, Suzanne Cole¹, Carl Orr⁵, Trudy McGarry⁵, Mary Canavan⁵, Stephan Kelly⁶, Costantino Pitzalis⁷, Tai-An Lin¹, Xuejun Liu¹, Susanna Proudman⁸, Douglas J. Veale⁹ and Sunil Nagpal¹, ¹Immunology, Janssen Research & Development, Spring House, PA, ²St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ³Flinders University, Adelaide, Australia, ⁴Royal Adelaide Hospital, Adelaide, Australia, ⁵St. Vincent's University Hospital, Dublin, Ireland, ⁶Queen Mary University of London, London, United Kingdom, ⁷Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁸University of Adelaide, Adelaide, Australia, ⁹Consultant Rheumatologist, Centre for Arthritis and Rheumatic Disease, St. Vincent’s University Hospital and University College Dublin, Dublin 4, Ireland
Background/Purpose: CD40 and CD40L (CD154) are tumor necrosis factor (TNF) family members involved in the pathogenesis of various autoimmune diseases. While this pathway is active…
Abstract Number: 2645 • 2016 ACR/ARHP Annual Meeting
Treatments for Early Rheumatoid Arthritis (RA): A Systematic Review of Randomized Controlled Trials
Salvador R. Garcia¹, Maria A. Lopez-Olivo² and Maria Suarez-Almazor³, ¹Department of Medicine. Section of Allergy Immunology and Rheumatology., Department of Medicine, Section of Allergy Immunology and Rheumatology, Baylor College of Medicine, Houston, Texas, USA., Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,, Houston, TX, ³Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: The objective of this systematic review was to evaluate the clinical evidence on the efficacy of different drug regimens for the treatment of early…
Abstract Number: 115 • 2016 ACR/ARHP Annual Meeting
Early Inflammatory Arthritis Presentation, Management and Outcomes in Canadian Aboriginal Patients
Sujay Nagaraj¹, Cheryl Barnabe², Orit Schieir³, Vivian P. Bykerk⁴, Janet Pope⁵, Shahin Jamal⁶, Gilles Boire⁷, Edward Keystone⁸, Diane Tin⁹, Boulos Haraoui¹⁰, J Carter Thorne¹¹, Carol Hitchon¹² and Canadian Early Arthritis Cohort (CATCH) Investigators, ¹McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, AB, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁸Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Institute de Rheumatologie, Montreal, QC, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Differences in access to care that influence the timing and quality of treatment interventions may create outcome inequities for Aboriginal patients with inflammatory arthritis.…
Abstract Number: 1266 • 2016 ACR/ARHP Annual Meeting
Predictors of Radiographic Progression in Early Rheumatoid Arthritis Patients Treated By an Aggressive Treat-to-Target Regimen
Nina P. Sundlisater¹, Siri Lillegraven¹, Inge C Olsen¹, Anna-Birgitte Aga¹, Till Uhlig¹, Hilde B. Hammer², D van der Heijde^1,3, Tore K. Kvien¹, Espen Haavardsholm¹ and ARCTIC study group, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept of Rheumatology, Leiden University Medical Ctr, Leiden, Netherlands
Background/Purpose: With implementation of tight control strategies and defined treatment targets in rheumatoid arthritis (RA) care, a majority of early RA patients may reach remission…
Abstract Number: 2987 • 2016 ACR/ARHP Annual Meeting
Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study
Roy Fleischmann¹, Gerd-Rüdiger Burmester², Bernard Combe³, Jeffrey R. Curtis⁴, Stephen Hall⁵, Boulos Haraoui⁶, Ronald van Vollenhoven⁷, Christopher Cioffi⁸, Cécile Ecoffet⁹, Lucian Ionescu⁹, Leon Gervitz¹⁰, Luke Peterson⁸ and Josef Smolen¹¹, ¹University of Texas Southwestern Medical Center at Dallas Metroplex Clinical Research Center, Dallas, TX, ²Charité – University Medicine Berlin, Berlin, Germany, ³Montpellier University Hospital, Montpellier, France, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Cabrini Medical Centre, Monash University, Melbourne, Australia, ⁶Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Brussels, Belgium, ¹⁰RA Patient Value Mission, UCB Pharma, Brussels, Belgium, ¹¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Head-to-head comparisons of biological (b)DMARDs in the treatment of RA should provide rigorous evidence on the comparative efficacy of different treatments. Although there are…
Abstract Number: 153 • 2016 ACR/ARHP Annual Meeting
Synovial Immunophenotype and Ultrasonography: A Contemporaneous Study of Different Compartments of the Knee Joint
Aurélie Najm^1,2, Carl Orr³, Benoît Le Goff MD PhD¹, Ursula Fearon⁴ and Douglas J. Veale⁵, ¹Rheumatology, Nantes University Hospital, Nantes, France, ²Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ³Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ⁴Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland, ⁵Consultant Rheumatologist, Centre for Arthritis and Rheumatic Disease, St. Vincent’s University Hospital and University College Dublin, Dublin 4, Ireland
Background/Purpose: Histological analysis of synovial tissue, despite being a reliable and accurate assessment for synovitis, is not routinely performed. Ultrasonography (US) is a fast, available…

« Previous Page
1
…
5
6
7
8
9
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.